PREVAIL Act Narrowly Moves Forward Despite Concerns About Drug Pricing Impact

Senator Chris Coons emphasized the importance of access to PTAB for generic companies and patient advocacy groups, ensuring they can challenge drug patents despite the PREVAIL Act's new requirements.

The PREVAIL Act's move from the Senate Judiciary Committee to the floor reflects the contentious debate on pharmaceutical patents and the role of tech companies in utilizing PTAB.

Read at IPWatchdog.com | Patents & Intellectual Property Law